Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06780306 · ClinicalTrials.gov registry record · Phase 2
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
A Phase 2 study, sponsored by BioTissue Holdings.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT06780306 is a Phase 2 study that has completed, run by BioTissue Holdings. The registered enrollment target is 74 participants.
The verdict
NCT06780306, a Phase 2 study, has completed, sponsored by BioTissue Holdings.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness. Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness. Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Interventions
- BIOLOGICAL TTAX03
- BIOLOGICAL Saline (NaCl 0,9 %) (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06780306
The ClinicalTrials.gov registry entry for NCT06780306 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioTissue Holdings, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TTAX03 is the first listed.
NCT06780306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06780306 about?
NCT06780306 is a clinical study titled "A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.". The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness. Researchers will compare 10mg of TTAX03 reconst...
What is the current status of trial NCT06780306?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2024-12-12. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT06780306?
The interventions under investigation include: TTAX03 (BIOLOGICAL), Saline (NaCl 0,9 %) (placebo) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06780306?
This trial is sponsored by BioTissue Holdings, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.